PacBio schedules November 4 results for Pacific Biosciences stock
Published on 10/27/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and operating metrics
- PacBio will report third-quarter results on November 4, 2026, after market close.
- Second-quarter consumables revenue rose 6.00 percent to USD 20.10 million.
- Pacific Biosciences stock costs EUR 2.22 at Lang & Schwarz on October 27, 2026 at 9:52 p.m. CEST.
- PacBio's 2026 revenue guidance stands at USD 155.00-165.00 million.
Pacific Biosciences of California (US69404D1081) will report its third-quarter 2026 results after market close on November 4, 2026, according to Pacific Biosciences. The scheduled report is the next clear test of whether clinical adoption can offset weaker instrument demand. Pacific Biosciences stock was trading at EUR 2.22 at Lang & Schwarz on October 27, 2026 at 9:52 p.m. CEST.
Clinical demand supports consumables
Second-quarter consumables revenue rose 6.00 percent year over year to USD 20.10 million, while clinical shipments increased 67.00 percent. EMEA revenue grew 52.00 percent to USD 14.40 million as hospitals moved from pilot programs toward routine sequencing, Yahoo Finance reported on October 27, 2026.
The operating mix remains uneven. Instrument revenue fell 9.00 percent year over year to USD 12.80 million, while Asia-Pacific revenue declined 45.00 percent to USD 7.00 million in the second quarter. PacBio shipped 20 Revio systems, including 60.00 percent to new customers, alongside 26 Vega systems.
Revenue guidance remains cautious
Second-quarter revenue reached USD 39.01 million, below the USD 42.90 million analyst estimate cited by Yahoo Finance. PacBio's 2026 revenue guidance is USD 155.00-165.00 million, and its non-GAAP gross-margin outlook is 35.00-37.00 percent. The company now expects cash-flow breakeven in 2028 rather than by the end of 2027, according to Yahoo Finance.
Price position and valuation
Pacific Biosciences had a market capitalization of USD 761.5 million as of October 27, 2026. Its Nasdaq price was USD 2.45 at 4:00 p.m. ET, while the 52-week range stood at USD 1.07 to USD 3.44 and volume reached 18,665,159 shares. The company operates in healthcare and medical devices, with sequencing systems, consumables and related software at the center of its business.
November date sets the next test
The company has scheduled its third-quarter earnings conference call for November 4, 2026, at 4:30 p.m. ET. The report will put the USD 155.00-165.00 million revenue outlook alongside clinical shipments, instrument demand and the path to cash-flow breakeven.
The next checkpoint
For investors, the key comparison is between growing clinical use and the pressure visible in instrument and Asia-Pacific revenue. The November 4 report should provide the next dated operating update.
The further course of trading is shown by the continuously updated real-time quote of Pacific Biosciences stock.
Pacific Biosciences at a glance
- Company: Pacific Biosciences of California, Inc.
- ISIN: US69404D1081
- Ticker: PACB
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 9:52 p.m. CEST): EUR 2.22
- Market capitalization: USD 761.5 million (as of October 27, 2026)
- 52-week range: USD 1.07-3.44 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report Nasdaq Composite.
